NanoPro - a Framework for Probiotically-Guided Nanovector Therapy

NanoPro enables ProTag-guided nanovector targeting of antigen-indistinct tumors, achieving antigen-specific transduction of 96.5% in MC-38 and 98.5% in MDA-MB-468.

• Why it matters: Targeted nanotherapy is limited by the “antigen problem,” where many nanoparticle targeting architectures lack matching addressable tumor receptors.
• What they did: The platform uses probiotically released ProTags—GFP or ALFA fused to the placenta growth factor-2 heparin-binding domain—produced by Escherichia coli Nissle 1917 with lpp deletion, boosting ProTag supernatant 16.5-fold.
• The result: ProTag-decorated bacterial supernatant enabled receptor-targeted aGFP- or aALFA-lentiviral vectors to transduce tumor cells with selective activity even at 625-fold dilution, supporting further study for tumor-restricted nanotherapeutic delivery.

AI summary of the abstract · may contain errors · not medical advice · read the paper.